Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

4.47USD
22 Sep 2017
Change (% chg)

$0.06 (+1.36%)
Prev Close
$4.41
Open
$4.37
Day's High
$4.52
Day's Low
$4.37
Volume
36,697
Avg. Vol
82,839
52-wk High
$12.58
52-wk Low
$2.93

Select another date:

Tue, Sep 19 2017

BRIEF-OncoMed CEO Paul Hastings to take medical leave of absence

* OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence

BRIEF-OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial

* OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial Source text for Eikon: Further company coverage:

BRIEF-Oncomed Pharmaceuticals Q2 loss per share $0.40

* Q2 revenue $6.2 million versus $6.7 million Source text for Eikon: Further company coverage:

BRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

* Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

BRIEF-BVF Partners reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17

* BVF Partners LP reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Oncomed reports workforce reduction

* Oncomed Pharmaceuticals Inc - oncomed will reduce its workforce by approximately 50 percent, resulting in 64 remaining full-time employees

OncoMed's lung cancer drug fails mid-stage study, shares tumble

OncoMed Pharmaceuticals Inc's shares were jolted for a second time in a week after the company said on Monday its experimental lung cancer drug failed a mid-stage study.

UPDATE 2-OncoMed's lung cancer drug fails mid-stage study, shares tumble

* To also discontinue enrollment in colorectal cancer drug trial

BRIEF-Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

* Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

OncoMed's lung cancer drug fails mid-stage study

April 17 OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.

Select another date: